Arcadia Biosciences (RKDA) Cash & Equivalents (2014 - 2025)

Arcadia Biosciences has reported Cash & Equivalents for 12 years, with the latest figure at $300000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 92.93% year-over-year to $300000.0; the trailing twelve-month figure through Dec 2025 stood at $300000.0 (down 92.93% YoY), and the FY2025 full-year result was $300000.0, down 92.93% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $300000.0, down from $1.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $44.0 million in Q2 2021, with the low at $300000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $15.3 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 340.55% — and 2025, when it plunged 92.93%.
• Arcadia Biosciences' Cash & Equivalents stood at $28.7 million in 2021, then dropped by 28.03% to $20.6 million in 2022, then slumped by 68.43% to $6.5 million in 2023, then plunged by 34.92% to $4.2 million in 2024, then sank by 92.93% to $300000.0 in 2025.
• The last three Cash & Equivalents figures came in at $300000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.